Dexclamol

Dexclamol
Clinical data
Other namesAY 24169
Identifiers
  • (1R,6R,8R)-6-propan-2-yl-3-azapentacyclo[11.8.1.03,8.09,22.016,21]docosa-9,11,13(22),16,18,20-hexaen-6-ol
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC24H29NO
Molar mass347.502 g·mol−1
3D model (JSmol)
  • CC(C)[C@]1(CCN2C[C@@H]3C4=CC=CC=C4CCC5=C3C(=CC=C5)[C@H]2C1)O
  • InChI=1S/C24H29NO/c1-16(2)24(26)12-13-25-15-21-19-8-4-3-6-17(19)10-11-18-7-5-9-20(23(18)21)22(25)14-24/h3-9,16,21-22,26H,10-15H2,1-2H3/t21-,22-,24-/m1/s1
  • Key:UPMOVJBGNREKJV-CQOQZXRMSA-N

Dexclamol (AY 24169) was an investigational new drug developed by McKenna and Harrison, Ltd. that was evaluated as a antipsychotic.[1][2][3][4] It acts as a dopamine receptor antagonist.[1]

See also

References

  1. ^ a b Humber LG, Bruderlein FT, Voith K (November 1975). "Neuroleptic agents of the benzocycloheptapyridoisoquinoline series. A hypothesis on their mode of interaction with the central dopamine receptor". Molecular Pharmacology. 11 (6): 833–840. PMID 1239657.
  2. ^ Elks J, Ganellin CR, eds. (1990). Dictionary of Drugs. Springer US. doi:10.1007/978-1-4757-2085-3. ISBN 978-1-4757-2087-7.
  3. ^ Castañer J, Paton DM (1976). "Dexclamol hydrochloride". Drugs of the Future. 1 (8): 366. doi:10.1358/dof.1976.001.08.1002521.
  4. ^ US 3657250, Bruderlein FT, Humber LG, "Benzocycloheptaisoquinoline derivatives", assigned to Ayerst Mckenna and Harrison Inc. 
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.